Grant: Collaborative Health Research Projects
University of Toronto
$252,500.00
Personalized Contingent Neurostimulation for Epilepsy by Machine Learning in Organic Brain Interfaces
FY 2020-21
Summary
Epilepsy is a chronic, neurological condition characterized by unpredictable, disabling
seizures. This devastating disorder increases mortality by 4 times and depression by 2 times
population rates. Unfortunately, epilepsy is extremely common, affecting 1 in 100 people, and
in 33% of cases, medications do not prevent seizures. An emerging technology to aid such
patients with drug-resistant epilepsy is contingent neurostimulation devices. These devices
are implanted in a patient so that they can detect epileptiform activity and electrically stimulate
the nervous system to prevent/abort seizures. Recently, two commercial contingent
neurostimulators have been approved for treating epilepsy. These devices have proven
successful at reducing seizure activity, however their efficacy is low. In particular, they are
very unlikely to produce seizure freedom, which is necessary to restore patient independence
and quality of life.
The primary reasons why existing neurostimulation devices have had such limited success
are that: (a) they use rudimentary (sparse and large) electrodes that poorly interface with the
brain and (b) they are extremely simplistic in their seizure detection and abortion capabilities
due to the use of basic electronics as constrained by energy limitations of an implant. We
propose to combine (a) the far superior brain-interfacing electrode technology from our
partner Panaxium and (b) our energy-efficient state-of-the-art implantable electronic circuits
that employ artificial intelligence for optimal seizure prediction and prevention - to greatly
improve the seizure-freedom efficacy of the neuromodulation therapy for intractable epilepsy.
Our team is uniquely well qualified for this project. It is led by an expert in low-power
biomedical and computational electronics (Genov), an epilepsy neurosurgeon and an expert
in brain neurophysiology (Valiante), and Panaxiums Technology Commercialization Leader
and a 20-year industry veteran (Weinroth).
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
549625-2020
Name nom
Genov, Roman
Department département
Electrical & Computer Engineering, Edward S. Rogers Sr. Department of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
252500
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
2504
Research subject group en
Electrical and electronic engineering
Research subject group fr
Génie électrique et électronique
Research subject en
Integrated circuits
Research subject fr
Circuits intégrés
Installment
inst:1 - 3
Partie
3
Nb partie
3
Application title
Personalized Contingent Neurostimulation for Epilepsy by Machine Learning in Organic Brain Interfaces
Keyword
NSERC
Application summary
Epilepsy is a chronic, neurological condition characterized by unpredictable, disabling
seizures. This devastating disorder increases mortality by 4 times and depression by 2 times
population rates. Unfortunately, epilepsy is extremely common, affecting 1 in 100 people, and
in 33% of cases, medications do not prevent seizures. An emerging technology to aid such
patients with drug-resistant epilepsy is contingent neurostimulation devices. These devices
are implanted in a patient so that they can detect epileptiform activity and electrically stimulate
the nervous system to prevent/abort seizures. Recently, two commercial contingent
neurostimulators have been approved for treating epilepsy. These devices have proven
successful at reducing seizure activity, however their efficacy is low. In particular, they are
very unlikely to produce seizure freedom, which is necessary to restore patient independence
and quality of life.
The primary reasons why existing neurostimulation devices have had such limited success
are that: (a) they use rudimentary (sparse and large) electrodes that poorly interface with the
brain and (b) they are extremely simplistic in their seizure detection and abortion capabilities
due to the use of basic electronics as constrained by energy limitations of an implant. We
propose to combine (a) the far superior brain-interfacing electrode technology from our
partner Panaxium and (b) our energy-efficient state-of-the-art implantable electronic circuits
that employ artificial intelligence for optimal seizure prediction and prevention - to greatly
improve the seizure-freedom efficacy of the neuromodulation therapy for intractable epilepsy.
Our team is uniquely well qualified for this project. It is led by an expert in low-power
biomedical and computational electronics (Genov), an epilepsy neurosurgeon and an expert
in brain neurophysiology (Valiante), and Panaxiums Technology Commercialization Leader
and a 20-year industry veteran (Weinroth).